Clinical evaluation of microbicide formulations

Kathleen M. Morrow, Craig Hendrix

Research output: Contribution to journalArticle

Abstract

The clinical evaluation of microbicide formulations presents variable and interacting challenges. Specific domains of acceptability, pharmacokinetics, and toxicity interact with each other to potentially inhibit or enhance a microbicide's efficacy. Each of these is further influenced by application and use parameters in the relative presence (or absence) of vaginal and/or seminal fluids, ultimately impacting effectiveness. Historically, acceptability of formulation and use parameters, and their concomitant behavioral influences, have been considered separately from pharmacokinetics and toxicity. While independent evaluation of these elements is necessary in some respects, we must acknowledge that this approach is not sufficient for the successful development of microbicides. Each needs to be considered in an integrated clinical evaluation strategy. This article presents the rationale for such an approach. This article forms part of a special supplement covering two presentations on clinical evaluation of microbicides from the symposium on " Recent Trends in Microbicide Formulations" held on 25 and 26 January 2010, Arlington, VA.

Original languageEnglish (US)
JournalAntiviral Research
Volume88
Issue numberSUPPL.
DOIs
StatePublished - Dec 2010

Fingerprint

Anti-Infective Agents
Pharmacokinetics

Keywords

  • Acceptability
  • Clinical evaluation
  • HIV prevention
  • Microbicide development
  • Pharmacokinetics
  • Toxicity

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

Clinical evaluation of microbicide formulations. / Morrow, Kathleen M.; Hendrix, Craig.

In: Antiviral Research, Vol. 88, No. SUPPL., 12.2010.

Research output: Contribution to journalArticle

Morrow, Kathleen M. ; Hendrix, Craig. / Clinical evaluation of microbicide formulations. In: Antiviral Research. 2010 ; Vol. 88, No. SUPPL.
@article{0bd527ae2f18488eaadaa8d961dc86a3,
title = "Clinical evaluation of microbicide formulations",
abstract = "The clinical evaluation of microbicide formulations presents variable and interacting challenges. Specific domains of acceptability, pharmacokinetics, and toxicity interact with each other to potentially inhibit or enhance a microbicide's efficacy. Each of these is further influenced by application and use parameters in the relative presence (or absence) of vaginal and/or seminal fluids, ultimately impacting effectiveness. Historically, acceptability of formulation and use parameters, and their concomitant behavioral influences, have been considered separately from pharmacokinetics and toxicity. While independent evaluation of these elements is necessary in some respects, we must acknowledge that this approach is not sufficient for the successful development of microbicides. Each needs to be considered in an integrated clinical evaluation strategy. This article presents the rationale for such an approach. This article forms part of a special supplement covering two presentations on clinical evaluation of microbicides from the symposium on {"} Recent Trends in Microbicide Formulations{"} held on 25 and 26 January 2010, Arlington, VA.",
keywords = "Acceptability, Clinical evaluation, HIV prevention, Microbicide development, Pharmacokinetics, Toxicity",
author = "Morrow, {Kathleen M.} and Craig Hendrix",
year = "2010",
month = "12",
doi = "10.1016/j.antiviral.2010.09.008",
language = "English (US)",
volume = "88",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "SUPPL.",

}

TY - JOUR

T1 - Clinical evaluation of microbicide formulations

AU - Morrow, Kathleen M.

AU - Hendrix, Craig

PY - 2010/12

Y1 - 2010/12

N2 - The clinical evaluation of microbicide formulations presents variable and interacting challenges. Specific domains of acceptability, pharmacokinetics, and toxicity interact with each other to potentially inhibit or enhance a microbicide's efficacy. Each of these is further influenced by application and use parameters in the relative presence (or absence) of vaginal and/or seminal fluids, ultimately impacting effectiveness. Historically, acceptability of formulation and use parameters, and their concomitant behavioral influences, have been considered separately from pharmacokinetics and toxicity. While independent evaluation of these elements is necessary in some respects, we must acknowledge that this approach is not sufficient for the successful development of microbicides. Each needs to be considered in an integrated clinical evaluation strategy. This article presents the rationale for such an approach. This article forms part of a special supplement covering two presentations on clinical evaluation of microbicides from the symposium on " Recent Trends in Microbicide Formulations" held on 25 and 26 January 2010, Arlington, VA.

AB - The clinical evaluation of microbicide formulations presents variable and interacting challenges. Specific domains of acceptability, pharmacokinetics, and toxicity interact with each other to potentially inhibit or enhance a microbicide's efficacy. Each of these is further influenced by application and use parameters in the relative presence (or absence) of vaginal and/or seminal fluids, ultimately impacting effectiveness. Historically, acceptability of formulation and use parameters, and their concomitant behavioral influences, have been considered separately from pharmacokinetics and toxicity. While independent evaluation of these elements is necessary in some respects, we must acknowledge that this approach is not sufficient for the successful development of microbicides. Each needs to be considered in an integrated clinical evaluation strategy. This article presents the rationale for such an approach. This article forms part of a special supplement covering two presentations on clinical evaluation of microbicides from the symposium on " Recent Trends in Microbicide Formulations" held on 25 and 26 January 2010, Arlington, VA.

KW - Acceptability

KW - Clinical evaluation

KW - HIV prevention

KW - Microbicide development

KW - Pharmacokinetics

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=78649407259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649407259&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2010.09.008

DO - 10.1016/j.antiviral.2010.09.008

M3 - Article

C2 - 21109067

AN - SCOPUS:78649407259

VL - 88

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - SUPPL.

ER -